AIP
SYRE icon

Ameritas Investment Partners’s Spyre Therapeutics SYRE Stock Holding History

Ameritas Investment Partners’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$600K Buy
6,760
+1,167
+21% +$85.2K 0.02% 827
2026
Q1 		$282K Hold
5,593
– – 0.01% 1070
2025
Q4 		$183K Buy
5,593
+1,427
+34% +$37.3K 0.01% 1310
2025
Q3 		$69.8K Sell
4,166
-925
-18% -$15.1K ﹤0.01% 1906
2025
Q2 		$76.2K Buy
5,091
+1,045
+26% +$15.5K ﹤0.01% 1920
2025
Q1 		$65.3K Buy
4,046
+654
+19% +$13.6K ﹤0.01% 1959
2024
Q4 		$79K Hold
3,392
– – ﹤0.01% 1920
2024
Q3 		$99.8K Hold
3,392
– – ﹤0.01% 1781
2024
Q2 		$79.7K Buy
+3,392
New +$114K ﹤0.01% 1872
2022
Q2 		– Sell
-148
Closed -$9K – 3227
2022
Q1 		$9K Hold
148
– – ﹤0.01% 2836
2021
Q4 		$18K Hold
148
– – ﹤0.01% 2695
2021
Q3 		$29K Hold
148
– – ﹤0.01% 2498
2021
Q2 		$26K Hold
148
– – ﹤0.01% 2599
2021
Q1 		$29K Hold
148
– – ﹤0.01% 2396
2020
Q4 		$29K Hold
148
– – ﹤0.01% 2296
2020
Q3 		$26K Hold
148
– – ﹤0.01% 2245
2020
Q2 		$34K Buy
148
+54
+57% +$10.3K ﹤0.01% 2070
2020
Q1 		$11K Buy
94
+39
+71% +$6.63K ﹤0.01% 2512
2019
Q4 		$11K Hold
55
– – ﹤0.01% 2703
2019
Q3 		$11K Hold
55
– – ﹤0.01% 2709
2019
Q2 		$9K Hold
55
– – ﹤0.01% 2835
2019
Q1 		$11K Hold
55
– – ﹤0.01% 2670
2018
Q4 		$10K Hold
55
– – ﹤0.01% 2674
2018
Q3 		$13K Hold
55
– – ﹤0.01% 2738
2018
Q2 		$15K Buy
+55
New +$13.5K ﹤0.01% 2669

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Ameritas Investment Partners's SYRE Position: Q2 2026 in Review

Ameritas Investment Partners increased its Spyre Therapeutics (SYRE) stake by 21% in Q2 2026, buying an estimated $85.2K and bringing the position to 6,760 shares worth $600K. The position accounts for 0.02% of the portfolio, ranked #827.

Ameritas Investment Partners first reported a position in SYRE in Q2 2018 and has held it in 25 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Ameritas Investment Partners held 6,760 shares of Spyre Therapeutics worth $600K as of Q2 2026.
  • Ameritas Investment Partners bought 1,167 Spyre Therapeutics shares in Q2 2026, an estimated $85.2K.
  • Spyre Therapeutics made up 0.02% of Ameritas Investment Partners's portfolio in Q2 2026, its #827 holding.
  • Ameritas Investment Partners first reported a position in Spyre Therapeutics in Q2 2018 and has held it in 25 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.